Compare Rockwell Automation (ROK) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rockwell Automation vs Sana Biotechnology Inc — how do they compare? Rockwell Automation trades at $446.44 (market cap $49.64B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Rockwell Automation is far larger — about 43.9× Sana Biotechnology Inc's market cap, and Rockwell Automation pays a 1.23% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| ROK | SANA | |
|---|---|---|
Market Cap | $49.64B | $1.13B |
Sector | Industrials | Health |
52-Week High | $495.08 | $5.92 |
52-Week Low | $333.75 | $2.68 |
Enterprise Value | $52.77B | $1.05B |
Dividend Yield | 1.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rockwell Automation (ROK) trades at $451.86, up 3.82% over 24 hours, with a neutral technical signal. The stock exhibits strong fundamentals, including a 49.09% gross margin and consistent earnings beats, with Q2 2026 EPS of $3.49 surpassing the $3.38 estimate. Recent news highlights AI integration in quality management systems, signaling innovation momentum. Valuation ratios are elevated, with a P/E of 41.85 and P/S of 5.6, reflecting premium pricing.
The outlook remains positive due to robust earnings performance and raised fiscal 2026 guidance, though high valuation multiples and inflation pressures pose risks. Analyst consensus is a Buy with a $507 price target, suggesting 12% upside. Key risks include cost inflation and competitive threats in industrial automation.
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
